MRI-guided Bone Marrow Biopsies of Prostate Cancer Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00165386|
Recruitment Status : Completed
First Posted : September 14, 2005
Last Update Posted : December 9, 2009
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Procedure: Magnetic Resonance Imaging Procedure: Bone Marrow Biopsy||Not Applicable|
- This study involves a one-time, MRI-guided bone marrow biopsy. Prior to this procedure, patients will need to have a bone scan performed within the last three months and a PSA blood test drawn within one month of registration to the study.
- Patients are also required to participate in the DFCI research study "Collection of Specimens and Clinical Data for Patients with Prostate Cancer or at High Risk for Prostate Cancer".
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||MRI-guided Bone Marrow Biopsies of Advanced CaP Patients|
|Study Start Date :||July 2001|
|Actual Primary Completion Date :||January 2006|
|Actual Study Completion Date :||January 2006|
- To compare the yield of detecting metastatic prostate cancer tissue using MRI-guided bone marrow needle biopsies to that of historical controls obtained through unguided biopsies.
- To evaluate the sensitivity of radiographic bone marrow changes detected by MRI for prostate cancer, as determined by the pathologic findings from bone marrow biopsy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00165386
|United States, Massachusetts|
|Dana-Farber Cancer Institute|
|Boston, Massachusetts, United States, 02115|
|Principal Investigator:||Mary-Ellen Taplin, MD||Dana-Farber Cancer Institute|